Urovant Sciences (NASDAQ:UROV) is scheduled to post its quarterly earnings results after the market closes on Tuesday, August 13th. Analysts expect Urovant Sciences to post earnings of ($0.92) per share for the quarter.
Urovant Sciences (NASDAQ:UROV) last issued its earnings results on Thursday, June 13th. The company reported ($0.96) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.96). On average, analysts expect Urovant Sciences to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.
Shares of NASDAQ:UROV traded up $0.08 on Wednesday, hitting $8.05. The stock had a trading volume of 1,247 shares, compared to its average volume of 19,934. Urovant Sciences has a twelve month low of $4.05 and a twelve month high of $14.49. The company has a quick ratio of 8.34, a current ratio of 8.34 and a debt-to-equity ratio of 0.18. The company has a 50 day moving average of $8.27. The company has a market cap of $244.09 million and a P/E ratio of -1.82.
Several equities research analysts have recently commented on the stock. JPMorgan Chase & Co. set a $24.00 target price on shares of Urovant Sciences and gave the company a “buy” rating in a research note on Friday, June 14th. Zacks Investment Research downgraded shares of Urovant Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, May 22nd. HC Wainwright set a $28.00 target price on shares of Urovant Sciences and gave the company a “buy” rating in a research note on Monday, June 24th. Finally, ValuEngine upgraded shares of Urovant Sciences from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $21.63.
About Urovant Sciences
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.
Further Reading: Why is the price-sales ratio important?
Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.